Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05XDZ
|
|||
| Former ID |
DIB007374
|
|||
| Drug Name |
LMT-X
|
|||
| Synonyms |
Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 3 | [1] | |
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [2], [3], [4] | ||
| Company |
TauRx Therapeutics Pte Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microtubule-associated protein tau (MAPT) | Target Info | Inhibitor | [3], [4], [5], [6] |
| TAR DNA binding protein 43 (TARDBP) | Target Info | Inhibitor | [3], [4] | |
| Tau protein aggregation (TauA) | Target Info | Modulator | [7] | |
| KEGG Pathway | MAPK signaling pathway | |||
| Alzheimer's disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reelin signaling pathway | ||||
| Reactome | Caspase-mediated cleavage of cytoskeletal proteins | |||
| WikiPathways | Notch Signaling Pathway | |||
| IL-2 Signaling Pathway | ||||
| MAPK Signaling Pathway | ||||
| Copper homeostasis | ||||
| Kit receptor signaling pathway | ||||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Alzheimers Disease | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| Apoptotic execution phase | ||||
| IL-5 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034429) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Clinical pipeline report, company report or official report of TauRx. | |||
| REF 6 | Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. | |||
| REF 7 | Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.